IBIO
iBio, Inc.
Key Financials
Net Income
$-18377000
↑ 26.2%
Operating Income
$-18602000
↓ 11.8%
Revenue
$400000
↑ 77.8%
Gross Profit
$2.2M
↑ 138.4%
Shareholders' Equity
$14.9M
↓ 30.2%
EPS (Diluted)
$-1.75
↑ 73.1%
Total Assets
$23.2M
↓ 19.3%
Cash & Equivalents
$8.6M
↓ 39.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K/A | 4/17/2026 | View on SEC |
| 8-K | 4/8/2026 | View on SEC |
| 4 | 3/27/2026 | View on SEC |
| 4 | 3/23/2026 | View on SEC |
| 4 | 3/23/2026 | View on SEC |
| 8-K | 3/9/2026 | View on SEC |
| EFFECT | 3/6/2026 | View on SEC |
| 424B5 | 3/6/2026 | View on SEC |
| CORRESP | 3/4/2026 | View on SEC |
| UPLOAD | 3/4/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IBIO |
| Company Name | iBio, Inc. |
| CIK | 1420720 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0630 |
| State of Incorporation | DE |
| Phone | 302 355-0650 |